+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Idiopathic Pulmonary Fibrosis (IPF) Market 2025-2029

  • PDF Icon

    Report

  • 218 Pages
  • February 2025
  • Region: Global
  • TechNavio
  • ID: 5780764
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The idiopathic pulmonary fibrosis (IPF) market is forecasted to grow by USD 1.60 billion during 2024-2029, accelerating at a CAGR of 6.9% during the forecast period. The report on the idiopathic pulmonary fibrosis (IPF) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of respiratory diseases, growing geriatric population, and increase in number of smokers.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The idiopathic pulmonary fibrosis (IPF) market is segmented as below:

By Route Of Administration

  • Oral
  • Parenteral

By Drug Class

  • Systemic corticosteroids
  • Immunosuppressants
  • Tyrosine kinase inhibitors
  • Anti-fibrotic agents

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increase in drug pipeline for IPF as one of the prime reasons driving the idiopathic pulmonary fibrosis (IPF) market growth during the next few years. Also, development of novel drugs for treatment of IPF and emergence of new patterns of IPF will lead to sizable demand in the market.

The report on the idiopathic pulmonary fibrosis (IPF) market covers the following areas:

  • Idiopathic Pulmonary Fibrosis (IPF) Market sizing
  • Idiopathic Pulmonary Fibrosis (IPF) Market forecast
  • Idiopathic Pulmonary Fibrosis (IPF) Market industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading idiopathic pulmonary fibrosis (IPF) market vendors that include Alembic Pharmaceuticals Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Inc., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics PLC, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, SHIONOGI Co. Ltd., and United Therapeutics Corp. Also, the idiopathic pulmonary fibrosis (IPF) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Market Segmentation by Drug Class
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023
Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023 ($ million)
5.2 Route of Administration segment analysis 2019 - 2023
Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
5.3 Drug Class segment analysis 2019 - 2023
Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
5.4 Distribution Channel segment analysis 2019 - 2023
Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
5.5 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.6 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 Impact of AI on Global Idiopathic Pulmonary Fibrosis (IPF) Market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Route of Administration
8.1 Market segments
Chart on Route of Administration - Market share 2024-2029 (%)
Data Table on Route of Administration - Market share 2024-2029 (%)
8.2 Comparison by Route of Administration
Chart on Comparison by Route of Administration
Data Table on Comparison by Route of Administration
8.3 Oral - Market size and forecast 2024-2029
Chart on Oral - Market size and forecast 2024-2029 ($ million)
Data Table on Oral - Market size and forecast 2024-2029 ($ million)
Chart on Oral - Year-over-year growth 2024-2029 (%)
Data Table on Oral - Year-over-year growth 2024-2029 (%)
8.4 Parenteral - Market size and forecast 2024-2029
Chart on Parenteral - Market size and forecast 2024-2029 ($ million)
Data Table on Parenteral - Market size and forecast 2024-2029 ($ million)
Chart on Parenteral - Year-over-year growth 2024-2029 (%)
Data Table on Parenteral - Year-over-year growth 2024-2029 (%)
8.5 Market opportunity by Route of Administration
Market opportunity by Route of Administration ($ million)
Data Table on Market opportunity by Route of Administration ($ million)
9 Market Segmentation by Drug Class
9.1 Market segments
Chart on Drug Class - Market share 2024-2029 (%)
Data Table on Drug Class - Market share 2024-2029 (%)
9.2 Comparison by Drug Class
Chart on Comparison by Drug Class
Data Table on Comparison by Drug Class
9.3 Systemic corticosteroids - Market size and forecast 2024-2029
Chart on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
Data Table on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
Chart on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
Data Table on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
9.4 Immunosuppressants - Market size and forecast 2024-2029
Chart on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
Data Table on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
Chart on Immunosuppressants - Year-over-year growth 2024-2029 (%)
Data Table on Immunosuppressants - Year-over-year growth 2024-2029 (%)
9.5 Tyrosine kinase inhibitors - Market size and forecast 2024-2029
Chart on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
Data Table on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
Chart on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
9.6 Anti-fibrotic agents - Market size and forecast 2024-2029
Chart on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
Data Table on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
Chart on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
Data Table on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
9.7 Market opportunity by Drug Class
Market opportunity by Drug Class ($ million)
Data Table on Market opportunity by Drug Class ($ million)
10 Market Segmentation by Distribution Channel
10.1 Market segments
Chart on Distribution Channel - Market share 2024-2029 (%)
Data Table on Distribution Channel - Market share 2024-2029 (%)
10.2 Comparison by Distribution Channel
Chart on Comparison by Distribution Channel
Data Table on Comparison by Distribution Channel
10.3 Hospital pharmacies - Market size and forecast 2024-2029
Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
10.4 Retail pharmacies - Market size and forecast 2024-2029
Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
10.5 Online pharmacies - Market size and forecast 2024-2029
Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
10.6 Market opportunity by Distribution Channel
Market opportunity by Distribution Channel ($ million)
Data Table on Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
11.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
12.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
12.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
12.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
12.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
12.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
12.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
12.8 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
12.9 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
12.10 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
12.11 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
12.12 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
12.13 Mexico - Market size and forecast 2024-2029
Chart on Mexico - Market size and forecast 2024-2029 ($ million)
Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
Chart on Mexico - Year-over-year growth 2024-2029 (%)
Data Table on Mexico - Year-over-year growth 2024-2029 (%)
12.14 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
12.15 Brazil - Market size and forecast 2024-2029
Chart on Brazil - Market size and forecast 2024-2029 ($ million)
Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
Chart on Brazil - Year-over-year growth 2024-2029 (%)
Data Table on Brazil - Year-over-year growth 2024-2029 (%)
12.16 Italy - Market size and forecast 2024-2029
Chart on Italy - Market size and forecast 2024-2029 ($ million)
Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Chart on Italy - Year-over-year growth 2024-2029 (%)
Data Table on Italy - Year-over-year growth 2024-2029 (%)
12.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
13 Drivers, Challenges, and Opportunity/Restraints
13.1 Market drivers
13.2 Market challenges
13.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
13.4 Market opportunities/restraints
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
Overview on factors of disruption
14.4 Industry risks
Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
Companies covered
15.2 Company ranking index
Company ranking index
15.3 Market positioning of companies
Matrix on companies position and classification
15.4 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product/Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
SWOT
15.5 Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH - Overview
Boehringer Ingelheim International GmbH - Product/Service
Boehringer Ingelheim International GmbH - Key news
Boehringer Ingelheim International GmbH - Key offerings
SWOT
15.6 Bristol Myers Squibb Co.
Bristol Myers Squibb Co. - Overview
Bristol Myers Squibb Co. - Product/Service
Bristol Myers Squibb Co. - Key news
Bristol Myers Squibb Co. - Key offerings
SWOT
15.7 Celix Pharma Ltd.
Celix Pharma Ltd. - Overview
Celix Pharma Ltd. - Product/Service
Celix Pharma Ltd. - Key offerings
SWOT
15.8 Cipla Inc.
Cipla Inc. - Overview
Cipla Inc. - Business segments
Cipla Inc. - Key news
Cipla Inc. - Key offerings
Cipla Inc. - Segment focus
SWOT
15.9 F. Hoffmann La Roche Ltd.
F. Hoffmann La Roche Ltd. - Overview
F. Hoffmann La Roche Ltd. - Business segments
F. Hoffmann La Roche Ltd. - Key news
F. Hoffmann La Roche Ltd. - Key offerings
F. Hoffmann La Roche Ltd. - Segment focus
SWOT
15.10 FibroGen Inc.
FibroGen Inc. - Overview
FibroGen Inc. - Product/Service
FibroGen Inc. - Key offerings
SWOT
15.11 Galapagos NV
Galapagos NV - Overview
Galapagos NV - Product/Service
Galapagos NV - Key offerings
SWOT
15.12 GNI Group Ltd.
GNI Group Ltd. - Overview
GNI Group Ltd. - Product/Service
GNI Group Ltd. - Key offerings
SWOT
15.13 Horizon Therapeutics Plc
Horizon Therapeutics Plc - Overview
Horizon Therapeutics Plc - Product/Service
Horizon Therapeutics Plc - Key offerings
SWOT
15.14 Jubilant Pharmova Ltd.
Jubilant Pharmova Ltd. - Overview
Jubilant Pharmova Ltd. - Business segments
Jubilant Pharmova Ltd. - Key news
Jubilant Pharmova Ltd. - Key offerings
Jubilant Pharmova Ltd. - Segment focus
SWOT
15.15 MediciNova Inc.
MediciNova Inc. - Overview
MediciNova Inc. - Product/Service
MediciNova Inc. - Key offerings
SWOT
15.16 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
SWOT
15.17 SHIONOGI Co. Ltd.
SHIONOGI Co. Ltd. - Overview
SHIONOGI Co. Ltd. - Product/Service
SHIONOGI Co. Ltd. - Key offerings
SWOT
15.18 United Therapeutics Corp.
United Therapeutics Corp. - Overview
United Therapeutics Corp. - Product/Service
United Therapeutics Corp. - Key offerings
SWOT
16 Appendix
16.1 Scope of the report
16.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
16.3 Currency conversion rates for US$
Currency conversion rates for US$
16.4 Research methodology
Research methodology
16.5 Data procurement
Information sources
16.6 Data validation
Data validation
16.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
16.8 Data synthesis
Data synthesis
16.9 360 degree market analysis
360 degree market analysis
16.10 List of abbreviations
List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 7: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 8: Executive Summary - Chart on Incremental Growth
Exhibits 9: Executive Summary - Data Table on Incremental Growth
Exhibits 10: Executive Summary - Chart on Company Market Positioning
Exhibits 11: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 12: Overview on criticality of inputs and factors of differentiation
Exhibits 13: Overview on factors of disruption
Exhibits 14: Impact of drivers and challenges in 2024 and 2029
Exhibits 15: Parent Market
Exhibits 16: Data Table on - Parent Market
Exhibits 17: Market characteristics analysis
Exhibits 18: Value chain analysis
Exhibits 19: Offerings of companies included in the market definition
Exhibits 20: Market segments
Exhibits 21: Chart on Global - Market size and forecast 2024-2029 ($ million)
Exhibits 22: Data Table on Global - Market size and forecast 2024-2029 ($ million)
Exhibits 23: Chart on Global Market: Year-over-year growth 2024-2029 (%)
Exhibits 24: Data Table on Global Market: Year-over-year growth 2024-2029 (%)
Exhibits 25: Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023 ($ million)
Exhibits 26: Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
Exhibits 27: Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
Exhibits 28: Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
Exhibits 29: Historic Market Size - Geography Segment 2019 - 2023 ($ million)
Exhibits 30: Historic Market Size - Country Segment 2019 - 2023 ($ million)
Exhibits 31: Five forces analysis - Comparison between 2024 and 2029
Exhibits 32: Bargaining power of buyers - Impact of key factors 2024 and 2029
Exhibits 33: Bargaining power of suppliers - Impact of key factors in 2024 and 2029
Exhibits 34: Threat of new entrants - Impact of key factors in 2024 and 2029
Exhibits 35: Threat of substitutes - Impact of key factors in 2024 and 2029
Exhibits 36: Threat of rivalry - Impact of key factors in 2024 and 2029
Exhibits 37: Chart on Market condition - Five forces 2024 and 2029
Exhibits 38: Chart on Route of Administration - Market share 2024-2029 (%)
Exhibits 39: Data Table on Route of Administration - Market share 2024-2029 (%)
Exhibits 40: Chart on Comparison by Route of Administration
Exhibits 41: Data Table on Comparison by Route of Administration
Exhibits 42: Chart on Oral - Market size and forecast 2024-2029 ($ million)
Exhibits 43: Data Table on Oral - Market size and forecast 2024-2029 ($ million)
Exhibits 44: Chart on Oral - Year-over-year growth 2024-2029 (%)
Exhibits 45: Data Table on Oral - Year-over-year growth 2024-2029 (%)
Exhibits 46: Chart on Parenteral - Market size and forecast 2024-2029 ($ million)
Exhibits 47: Data Table on Parenteral - Market size and forecast 2024-2029 ($ million)
Exhibits 48: Chart on Parenteral - Year-over-year growth 2024-2029 (%)
Exhibits 49: Data Table on Parenteral - Year-over-year growth 2024-2029 (%)
Exhibits 50: Market opportunity by Route of Administration ($ million)
Exhibits 51: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits 52: Chart on Drug Class - Market share 2024-2029 (%)
Exhibits 53: Data Table on Drug Class - Market share 2024-2029 (%)
Exhibits 54: Chart on Comparison by Drug Class
Exhibits 55: Data Table on Comparison by Drug Class
Exhibits 56: Chart on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
Exhibits 57: Data Table on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
Exhibits 58: Chart on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
Exhibits 59: Data Table on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
Exhibits 60: Chart on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
Exhibits 61: Data Table on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
Exhibits 62: Chart on Immunosuppressants - Year-over-year growth 2024-2029 (%)
Exhibits 63: Data Table on Immunosuppressants - Year-over-year growth 2024-2029 (%)
Exhibits 64: Chart on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
Exhibits 65: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
Exhibits 66: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
Exhibits 67: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
Exhibits 68: Chart on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
Exhibits 69: Data Table on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
Exhibits 70: Chart on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
Exhibits 71: Data Table on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
Exhibits 72: Market opportunity by Drug Class ($ million)
Exhibits 73: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 74: Chart on Distribution Channel - Market share 2024-2029 (%)
Exhibits 75: Data Table on Distribution Channel - Market share 2024-2029 (%)
Exhibits 76: Chart on Comparison by Distribution Channel
Exhibits 77: Data Table on Comparison by Distribution Channel
Exhibits 78: Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 79: Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 80: Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 81: Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 82: Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 83: Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 84: Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 85: Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 86: Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 87: Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 88: Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 89: Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 90: Market opportunity by Distribution Channel ($ million)
Exhibits 91: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 92: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 93: Chart on Market share By Geographical Landscape 2024-2029 (%)
Exhibits 94: Data Table on Market share By Geographical Landscape 2024-2029 (%)
Exhibits 95: Chart on Geographic comparison
Exhibits 96: Data Table on Geographic comparison
Exhibits 97: Chart on North America - Market size and forecast 2024-2029 ($ million)
Exhibits 98: Data Table on North America - Market size and forecast 2024-2029 ($ million)
Exhibits 99: Chart on North America - Year-over-year growth 2024-2029 (%)
Exhibits 100: Data Table on North America - Year-over-year growth 2024-2029 (%)
Exhibits 101: Chart on Europe - Market size and forecast 2024-2029 ($ million)
Exhibits 102: Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Exhibits 103: Chart on Europe - Year-over-year growth 2024-2029 (%)
Exhibits 104: Data Table on Europe - Year-over-year growth 2024-2029 (%)
Exhibits 105: Chart on Asia - Market size and forecast 2024-2029 ($ million)
Exhibits 106: Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Exhibits 107: Chart on Asia - Year-over-year growth 2024-2029 (%)
Exhibits 108: Data Table on Asia - Year-over-year growth 2024-2029 (%)
Exhibits 109: Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Exhibits 110: Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Exhibits 111: Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Exhibits 112: Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Exhibits 113: Chart on US - Market size and forecast 2024-2029 ($ million)
Exhibits 114: Data Table on US - Market size and forecast 2024-2029 ($ million)
Exhibits 115: Chart on US - Year-over-year growth 2024-2029 (%)
Exhibits 116: Data Table on US - Year-over-year growth 2024-2029 (%)
Exhibits 117: Chart on Canada - Market size and forecast 2024-2029 ($ million)
Exhibits 118: Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Exhibits 119: Chart on Canada - Year-over-year growth 2024-2029 (%)
Exhibits 120: Data Table on Canada - Year-over-year growth 2024-2029 (%)
Exhibits 121: Chart on China - Market size and forecast 2024-2029 ($ million)
Exhibits 122: Data Table on China - Market size and forecast 2024-2029 ($ million)
Exhibits 123: Chart on China - Year-over-year growth 2024-2029 (%)
Exhibits 124: Data Table on China - Year-over-year growth 2024-2029 (%)
Exhibits 125: Chart on Japan - Market size and forecast 2024-2029 ($ million)
Exhibits 126: Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Exhibits 127: Chart on Japan - Year-over-year growth 2024-2029 (%)
Exhibits 128: Data Table on Japan - Year-over-year growth 2024-2029 (%)
Exhibits 129: Chart on Germany - Market size and forecast 2024-2029 ($ million)
Exhibits 130: Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Exhibits 131: Chart on Germany - Year-over-year growth 2024-2029 (%)
Exhibits 132: Data Table on Germany - Year-over-year growth 2024-2029 (%)
Exhibits 133: Chart on UK - Market size and forecast 2024-2029 ($ million)
Exhibits 134: Data Table on UK - Market size and forecast 2024-2029 ($ million)
Exhibits 135: Chart on UK - Year-over-year growth 2024-2029 (%)
Exhibits 136: Data Table on UK - Year-over-year growth 2024-2029 (%)
Exhibits 137: Chart on Mexico - Market size and forecast 2024-2029 ($ million)
Exhibits 138: Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
Exhibits 139: Chart on Mexico - Year-over-year growth 2024-2029 (%)
Exhibits 140: Data Table on Mexico - Year-over-year growth 2024-2029 (%)
Exhibits 141: Chart on France - Market size and forecast 2024-2029 ($ million)
Exhibits 142: Data Table on France - Market size and forecast 2024-2029 ($ million)
Exhibits 143: Chart on France - Year-over-year growth 2024-2029 (%)
Exhibits 144: Data Table on France - Year-over-year growth 2024-2029 (%)
Exhibits 145: Chart on Brazil - Market size and forecast 2024-2029 ($ million)
Exhibits 146: Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
Exhibits 147: Chart on Brazil - Year-over-year growth 2024-2029 (%)
Exhibits 148: Data Table on Brazil - Year-over-year growth 2024-2029 (%)
Exhibits 149: Chart on Italy - Market size and forecast 2024-2029 ($ million)
Exhibits 150: Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Exhibits 151: Chart on Italy - Year-over-year growth 2024-2029 (%)
Exhibits 152: Data Table on Italy - Year-over-year growth 2024-2029 (%)
Exhibits 153: Market opportunity By Geographical Landscape ($ million)
Exhibits 154: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 155: Impact of drivers and challenges in 2024 and 2029
Exhibits 156: Overview on criticality of inputs and factors of differentiation
Exhibits 157: Overview on factors of disruption
Exhibits 158: Impact of key risks on business
Exhibits 159: Companies covered
Exhibits 160: Company ranking index
Exhibits 161: Matrix on companies position and classification
Exhibits 162: AstraZeneca Plc - Overview
Exhibits 163: AstraZeneca Plc - Product/Service
Exhibits 164: AstraZeneca Plc - Key news
Exhibits 165: AstraZeneca Plc - Key offerings
Exhibits 166: SWOT
Exhibits 167: Boehringer Ingelheim International GmbH - Overview
Exhibits 168: Boehringer Ingelheim International GmbH - Product/Service
Exhibits 169: Boehringer Ingelheim International GmbH - Key news
Exhibits 170: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 171: SWOT
Exhibits 172: Bristol Myers Squibb Co. - Overview
Exhibits 173: Bristol Myers Squibb Co. - Product/Service
Exhibits 174: Bristol Myers Squibb Co. - Key news
Exhibits 175: Bristol Myers Squibb Co. - Key offerings
Exhibits 176: SWOT
Exhibits 177: Celix Pharma Ltd. - Overview
Exhibits 178: Celix Pharma Ltd. - Product/Service
Exhibits 179: Celix Pharma Ltd. - Key offerings
Exhibits 180: SWOT
Exhibits 181: Cipla Inc. - Overview
Exhibits 182: Cipla Inc. - Business segments
Exhibits 183: Cipla Inc. - Key news
Exhibits 184: Cipla Inc. - Key offerings
Exhibits 185: Cipla Inc. - Segment focus
Exhibits 186: SWOT
Exhibits 187: F. Hoffmann La Roche Ltd. - Overview
Exhibits 188: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 189: F. Hoffmann La Roche Ltd. - Key news
Exhibits 190: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 191: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 192: SWOT
Exhibits 193: FibroGen Inc. - Overview
Exhibits 194: FibroGen Inc. - Product/Service
Exhibits 195: FibroGen Inc. - Key offerings
Exhibits 196: SWOT
Exhibits 197: Galapagos NV - Overview
Exhibits 198: Galapagos NV - Product/Service
Exhibits 199: Galapagos NV - Key offerings
Exhibits 200: SWOT
Exhibits 201: GNI Group Ltd. - Overview
Exhibits 202: GNI Group Ltd. - Product/Service
Exhibits 203: GNI Group Ltd. - Key offerings
Exhibits 204: SWOT
Exhibits 205: Horizon Therapeutics Plc - Overview
Exhibits 206: Horizon Therapeutics Plc - Product/Service
Exhibits 207: Horizon Therapeutics Plc - Key offerings
Exhibits 208: SWOT
Exhibits 209: Jubilant Pharmova Ltd. - Overview
Exhibits 210: Jubilant Pharmova Ltd. - Business segments
Exhibits 211: Jubilant Pharmova Ltd. - Key news
Exhibits 212: Jubilant Pharmova Ltd. - Key offerings
Exhibits 213: Jubilant Pharmova Ltd. - Segment focus
Exhibits 214: SWOT
Exhibits 215: MediciNova Inc. - Overview
Exhibits 216: MediciNova Inc. - Product/Service
Exhibits 217: MediciNova Inc. - Key offerin

Executive Summary

The following companies are recognized as the key players in the global idiopathic pulmonary fibrosis (IPF) market: Alembic Pharmaceuticals Ltd., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Inc., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, SHIONOGI Co. Ltd., and United Therapeutics Corp..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in drug pipeline for ipf."

According to the report, one of the major drivers for this market is the increasing prevalence of respiratory diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alembic Pharmaceuticals Ltd.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Celix Pharma Ltd.
  • Cipla Inc.
  • Daewoong Pharmaceutical Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • FibroGen Inc.
  • Galapagos NV
  • Galecto Inc.
  • GNI Group Ltd.
  • Horizon Therapeutics Plc
  • Intas Pharmaceuticals Ltd.
  • Jubilant Pharmova Ltd.
  • MediciNova Inc.
  • Merck and Co. Inc.
  • Mission Therapeutics
  • Novartis AG
  • SHIONOGI Co. Ltd.
  • United Therapeutics Corp.